APX 5278

Drug Profile

APX 5278

Alternative Names: APTA-5278; APX-5278

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator AptaBio Therapeutics
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action NADPH oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Atherosclerosis

Most Recent Events

  • 13 Feb 2017 Early research in Atherosclerosis in South Korea before February 2017 (AptaBio Therapeutics pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top